Evidence map›Paper›PMID 40653654›Full record

ArticleJournal of medicinal chemistry2025

Fragment-Based Development of Small Molecule Inhibitors Targeting

Madeline E Kavanagh, Kirsty J McLean, Sophie H Gilbert, Cecilia N Amadi, Matthew Snee, Richard B Tunnicliffe, Kriti Arora, Helena I M Boshoff, Alexander Fanourakis, Maria Jose Rebollo-Lopez and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Madeline E KavanaghYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.ORCID 0000-0002-4735-1559
Kirsty J McLeanCentre for Synthetic Biology of Fine and Specialty Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.ORCID 0000-0002-7193-5044
Sophie H GilbertYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.
Cecilia N AmadiCentre for Synthetic Biology of Fine and Specialty Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.ORCID 0000-0002-2724-4262
Matthew SneeCentre for Synthetic Biology of Fine and Specialty Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.
Richard B TunnicliffeCentre for Synthetic Biology of Fine and Specialty Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.
Kriti AroraTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, Maryland 20892, United States.
Helena I M BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID 0000-0002-4333-206X
Alexander FanourakisYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.
Maria Jose Rebollo-LopezGlobal Health R&D, GSK, Severo Ochoa 2, Tres Cantos 28760, Spain.
Fatima OrtegaGlobal Health R&D, GSK, Severo Ochoa 2, Tres Cantos 28760, Spain.
Colin W LevyManchester Protein Structure Facility (MPSF), Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, U.K.
Andrew W MunroCentre for Synthetic Biology of Fine and Specialty Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.ORCID 0000-0002-4642-180X
David LeysDepartment of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.ORCID 0000-0003-4845-8443
Chris AbellYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.ORCID 0000-0001-9174-1987
Anthony G CoyneYusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, U.K.ORCID 0000-0003-0205-5630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis is the deadliest infectious disease in history and new drugs are urgently required to combat multidrug-resistant (MDR) strains of

Indexed as

Antitubercular AgentsCholesterolMycobacterium tuberculosisSmall Molecule LibrariesCytochrome P-450 Enzyme SystemDrug DesignHumansMicrobial Sensitivity TestsStructure-Activity RelationshipAntitubercular AgentsCholesterolCytochrome P-450 Enzyme SystemSmall Molecule Libraries

Identifiers

PMID40653654
PMCPMC12305662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.